Compare ADMA Biologics Inc (ADMA) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Williams-Sonoma, Inc. — how do they compare? ADMA Biologics Inc trades at $9.29 (market cap $2.13B), while Williams-Sonoma, Inc. trades at $216.7 (market cap $26.36B). The key difference: Williams-Sonoma, Inc. is far larger — about 12.4× ADMA Biologics Inc's market cap, and Williams-Sonoma, Inc. pays a 1.36% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | WSM | |
|---|---|---|
Market Cap | $2.13B | $26.36B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $240.06 |
52-Week Low | $7.60 | $163.62 |
Enterprise Value | $2.20B | $27.20B |
Dividend Yield | — | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Williams-Sonoma (WSM) trades at $222.49, down 2.22% today, with a bullish technical signal and strong profitability metrics including 54.01% ROE and 13.81% net margin. The stock has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $2.03. Recent news highlights brand collaborations and dividend declarations, while cash flow trends show operational strength despite net outflows in 2025.
WSM presents a mixed outlook with robust fundamentals and analyst consensus leaning hold (60.72%), but risks include competitive pressures and macroeconomic sensitivity. The current price sits above the $215.50 consensus target, suggesting limited near-term upside despite strong operational performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
